Tapewire

Nasdaq · USD

TNDM

TANDEM DIABETES CARE INC

Export transactions ↓
Tapewire entity
4682
SEC CIK
0001438133
Parsed reports
672

Last 12 months

Inside the activity.

0 purchase rows · 2 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202500
Dec 202500
Jan 202600
Feb 202600
Mar 202602
Apr 202600
May 202600
Jun 202600
Jul 202600
Aug 202600
Sep 202600
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
March 16, 2026 Filed Mar 18, 2026 20:06 UTC
Novara Mark DavidEVP & CHIEF COMMERCIAL OFFICER
Exercise / conversionRestricted Stock Unit · Derivative 7,414 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000023 · wk-form4_1773864360.xml · derivative · entry 4

Novara Mark David · CIK 0002000342 · EVP & CHIEF COMMERCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,244

Underlying: Common Stock · 7,414 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: Awarded on December 15, 2023 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).

F4 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.

F5 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 12/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

F5 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 12/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

Read SEC document
March 16, 2026 Filed Mar 18, 2026 20:06 UTC
Novara Mark DavidEVP & CHIEF COMMERCIAL OFFICER
Tax withholdingCommon Stock 5,540 $21.59 $119,608.60
Disclosure

SEC source: 0001438133-26-000023 · wk-form4_1773864360.xml · nonDerivative · entry 2

Novara Mark David · CIK 0002000342 · EVP & CHIEF COMMERCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,843

F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Read SEC document
March 16, 2026 Filed Mar 18, 2026 20:06 UTC
Novara Mark DavidEVP & CHIEF COMMERCIAL OFFICER
Exercise / conversionCommon Stock 7,414 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000023 · wk-form4_1773864360.xml · nonDerivative · entry 1

Novara Mark David · CIK 0002000342 · EVP & CHIEF COMMERCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,383

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
March 05, 2026 Filed Mar 9, 2026 20:27 UTC
Novara Mark DavidEVP & CHIEF COMMERCIAL OFFICER
SaleCommon Stock 2 $22.81 $45.62
Disclosure

SEC source: 0001438133-26-000022 · wk-form4_1773088030.xml · nonDerivative · entry 1

Novara Mark David · CIK 0002000342 · EVP & CHIEF COMMERCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 35,969

F1 · kind: The shares were sold, pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 4, 2025.

Read SEC document
February 17, 2026 Filed Feb 19, 2026 21:37 UTC
Gasser Elizabeth AnneEVP, Chief Strategy Officer
Exercise / conversionRestricted Stock Unit · Derivative 1,097 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000019 · wk-form4_1771537052.xml · derivative · entry 7

Gasser Elizabeth Anne · CIK 0001866283 · EVP, Chief Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,484

Underlying: Common Stock · 1,097 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · security: Awarded on May 23, 2024 pursuant to the 2023 Plan.

F4 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.

F7 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

F7 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

Read SEC document
February 17, 2026 Filed Feb 19, 2026 21:37 UTC
Gasser Elizabeth AnneEVP, Chief Strategy Officer
Exercise / conversionRestricted Stock Unit · Derivative 1,503 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000019 · wk-form4_1771537052.xml · derivative · entry 6

Gasser Elizabeth Anne · CIK 0001866283 · EVP, Chief Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,503

Underlying: Common Stock · 1,503 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: Awarded on May 25, 2023 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).

F4 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.

F5 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

F5 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

Read SEC document
February 17, 2026 Filed Feb 19, 2026 21:37 UTC
Gasser Elizabeth AnneEVP, Chief Strategy Officer
Tax withholdingCommon Stock 647 $18.95 $12,260.65
Disclosure

SEC source: 0001438133-26-000019 · wk-form4_1771537052.xml · nonDerivative · entry 4

Gasser Elizabeth Anne · CIK 0001866283 · EVP, Chief Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,066

F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Read SEC document
February 17, 2026 Filed Feb 19, 2026 21:37 UTC
Gasser Elizabeth AnneEVP, Chief Strategy Officer
Exercise / conversionCommon Stock 1,097 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000019 · wk-form4_1771537052.xml · nonDerivative · entry 3

Gasser Elizabeth Anne · CIK 0001866283 · EVP, Chief Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,713

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 17, 2026 Filed Feb 19, 2026 21:37 UTC
Gasser Elizabeth AnneEVP, Chief Strategy Officer
Tax withholdingCommon Stock 887 $18.95 $16,808.65
Disclosure

SEC source: 0001438133-26-000019 · wk-form4_1771537052.xml · nonDerivative · entry 2

Gasser Elizabeth Anne · CIK 0001866283 · EVP, Chief Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 616

F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Read SEC document
February 17, 2026 Filed Feb 19, 2026 21:37 UTC
Gasser Elizabeth AnneEVP, Chief Strategy Officer
Exercise / conversionCommon Stock 1,503 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000019 · wk-form4_1771537052.xml · nonDerivative · entry 1

Gasser Elizabeth Anne · CIK 0001866283 · EVP, Chief Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,503

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 17, 2026 Filed Feb 19, 2026 21:34 UTC
Vosseller LeighEVP & CHIEF FINANCIAL OFFICER
Exercise / conversionRestricted Stock Unit · Derivative 1,495 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000013 · wk-form4_1771536848.xml · derivative · entry 7

Vosseller Leigh · CIK 0001726322 · EVP & CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,478

Underlying: Common Stock · 1,495 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · security: Awarded on May 23, 2024 pursuant to the 2023 Plan.

F4 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.

F7 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

F7 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

Read SEC document
February 17, 2026 Filed Feb 19, 2026 21:34 UTC
Vosseller LeighEVP & CHIEF FINANCIAL OFFICER
Exercise / conversionRestricted Stock Unit · Derivative 1,503 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000013 · wk-form4_1771536848.xml · derivative · entry 6

Vosseller Leigh · CIK 0001726322 · EVP & CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,503

Underlying: Common Stock · 1,503 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: Awarded on May 25, 2023 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).

F4 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.

F5 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

F5 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

Read SEC document
February 17, 2026 Filed Feb 19, 2026 21:34 UTC
Vosseller LeighEVP & CHIEF FINANCIAL OFFICER
Tax withholdingCommon Stock 616 $18.95 $11,673.20
Disclosure

SEC source: 0001438133-26-000013 · wk-form4_1771536848.xml · nonDerivative · entry 4

Vosseller Leigh · CIK 0001726322 · EVP & CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,411

F1 · shares: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Read SEC document
February 17, 2026 Filed Feb 19, 2026 21:34 UTC
Vosseller LeighEVP & CHIEF FINANCIAL OFFICER
Exercise / conversionCommon Stock 1,495 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000013 · wk-form4_1771536848.xml · nonDerivative · entry 3

Vosseller Leigh · CIK 0001726322 · EVP & CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,027

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 17, 2026 Filed Feb 19, 2026 21:34 UTC
Vosseller LeighEVP & CHIEF FINANCIAL OFFICER
Tax withholdingCommon Stock 619 $18.95 $11,730.05
Disclosure

SEC source: 0001438133-26-000013 · wk-form4_1771536848.xml · nonDerivative · entry 2

Vosseller Leigh · CIK 0001726322 · EVP & CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,532

F1 · shares: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Read SEC document
February 17, 2026 Filed Feb 19, 2026 21:34 UTC
Vosseller LeighEVP & CHIEF FINANCIAL OFFICER
Exercise / conversionCommon Stock 1,503 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000013 · wk-form4_1771536848.xml · nonDerivative · entry 1

Vosseller Leigh · CIK 0001726322 · EVP & CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,151

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 17, 2026 Filed Feb 19, 2026 21:36 UTC
Morrison SusanEVP & Chief Admin. Officer
Exercise / conversionRestricted Stock Unit · Derivative 1,097 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000017 · wk-form4_1771537009.xml · derivative · entry 6

Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,484

Underlying: Common Stock · 1,097 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · security: Awarded on May 23, 2024 pursuant to the 2023 Plan.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.

F6 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

F6 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

Read SEC document
February 17, 2026 Filed Feb 19, 2026 21:36 UTC
Morrison SusanEVP & Chief Admin. Officer
Exercise / conversionRestricted Stock Unit · Derivative 1,503 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000017 · wk-form4_1771537009.xml · derivative · entry 5

Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,503

Underlying: Common Stock · 1,503 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Awarded on May 25, 2023 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.

F4 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

F4 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

Read SEC document
February 17, 2026 Filed Feb 19, 2026 21:36 UTC
Morrison SusanEVP & Chief Admin. Officer
Tax withholdingCommon Stock 372 $18.95 $7,049.40
Disclosure

SEC source: 0001438133-26-000017 · wk-form4_1771537009.xml · nonDerivative · entry 4

Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,635

F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Read SEC document
February 17, 2026 Filed Feb 19, 2026 21:36 UTC
Morrison SusanEVP & Chief Admin. Officer
Exercise / conversionCommon Stock 1,097 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000017 · wk-form4_1771537009.xml · nonDerivative · entry 3

Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,007

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 17, 2026 Filed Feb 19, 2026 21:36 UTC
Morrison SusanEVP & Chief Admin. Officer
Tax withholdingCommon Stock 510 $18.95 $9,664.50
Disclosure

SEC source: 0001438133-26-000017 · wk-form4_1771537009.xml · nonDerivative · entry 2

Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,910

F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Read SEC document
February 17, 2026 Filed Feb 19, 2026 21:36 UTC
Morrison SusanEVP & Chief Admin. Officer
Exercise / conversionCommon Stock 1,503 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000017 · wk-form4_1771537009.xml · nonDerivative · entry 1

Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,420

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 17, 2026 Filed Feb 19, 2026 21:37 UTC
Carpenter RickChief Technology Officer
Exercise / conversionRestricted Stock Unit · Derivative 897 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000020 · wk-form4_1771537073.xml · derivative · entry 6

Carpenter Rick · CIK 0001513889 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,487

Underlying: Common Stock · 897 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · security: Awarded on May 23, 2024 pursuant to the 2023 Plan.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.

F6 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

F6 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

Read SEC document
February 17, 2026 Filed Feb 19, 2026 21:37 UTC
Carpenter RickChief Technology Officer
Exercise / conversionRestricted Stock Unit · Derivative 1,437 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000020 · wk-form4_1771537073.xml · derivative · entry 5

Carpenter Rick · CIK 0001513889 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,437

Underlying: Common Stock · 1,437 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Awarded on May 25, 2023 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan (the 2023 Plan).

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.

F4 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

F4 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

Read SEC document
February 17, 2026 Filed Feb 19, 2026 21:37 UTC
Carpenter RickChief Technology Officer
Tax withholdingCommon Stock 504 $18.95 $9,550.80
Disclosure

SEC source: 0001438133-26-000020 · wk-form4_1771537073.xml · nonDerivative · entry 4

Carpenter Rick · CIK 0001513889 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,274

F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Read SEC document
February 17, 2026 Filed Feb 19, 2026 21:37 UTC
Carpenter RickChief Technology Officer
Exercise / conversionCommon Stock 897 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000020 · wk-form4_1771537073.xml · nonDerivative · entry 3

Carpenter Rick · CIK 0001513889 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,778

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 17, 2026 Filed Feb 19, 2026 21:37 UTC
Carpenter RickChief Technology Officer
Tax withholdingCommon Stock 808 $18.95 $15,311.60
Disclosure

SEC source: 0001438133-26-000020 · wk-form4_1771537073.xml · nonDerivative · entry 2

Carpenter Rick · CIK 0001513889 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,881

F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Read SEC document
February 17, 2026 Filed Feb 19, 2026 21:37 UTC
Carpenter RickChief Technology Officer
Exercise / conversionCommon Stock 1,437 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000020 · wk-form4_1771537073.xml · nonDerivative · entry 1

Carpenter Rick · CIK 0001513889 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,689

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 17, 2026 Filed Feb 19, 2026 21:36 UTC
Novara Mark DavidEVP & CHIEF COMMERCIAL OFFICER
Exercise / conversionRestricted Stock Unit · Derivative 77 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000016 · wk-form4_1771536990.xml · derivative · entry 3

Novara Mark David · CIK 0002000342 · EVP & CHIEF COMMERCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 380

Underlying: Common Stock · 77 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Awarded on May 23, 2024 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.

F4 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

F4 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

Read SEC document
February 17, 2026 Filed Feb 19, 2026 21:36 UTC
Novara Mark DavidEVP & CHIEF COMMERCIAL OFFICER
Tax withholdingCommon Stock 62 $18.95 $1,174.90
Disclosure

SEC source: 0001438133-26-000016 · wk-form4_1771536990.xml · nonDerivative · entry 2

Novara Mark David · CIK 0002000342 · EVP & CHIEF COMMERCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,971

F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Read SEC document
February 17, 2026 Filed Feb 19, 2026 21:36 UTC
Novara Mark DavidEVP & CHIEF COMMERCIAL OFFICER
Exercise / conversionCommon Stock 77 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000016 · wk-form4_1771536990.xml · nonDerivative · entry 1

Novara Mark David · CIK 0002000342 · EVP & CHIEF COMMERCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,033

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 17, 2026 Filed Feb 19, 2026 21:34 UTC
Sheridan John FDirector · PRESIDENT & CEO
Exercise / conversionRestricted Stock Unit · Derivative 5,983 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000014 · wk-form4_1771536871.xml · derivative · entry 6

Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,911

Underlying: Common Stock · 5,983 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · security: Awarded on May 23, 2024 pursuant to the 2023 Plan, as amended.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.

F6 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

F6 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

Read SEC document
February 17, 2026 Filed Feb 19, 2026 21:34 UTC
Sheridan John FDirector · PRESIDENT & CEO
Exercise / conversionRestricted Stock Unit · Derivative 5,471 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000014 · wk-form4_1771536871.xml · derivative · entry 5

Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,472

Underlying: Common Stock · 5,471 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Awarded on May 25, 2023 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.

F4 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

F4 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

Read SEC document
February 17, 2026 Filed Feb 19, 2026 21:34 UTC
Sheridan John FDirector · PRESIDENT & CEO
Tax withholdingCommon Stock 2,400 $18.95 $45,480.00
Disclosure

SEC source: 0001438133-26-000014 · wk-form4_1771536871.xml · nonDerivative · entry 4

Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 124,691

F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Read SEC document
February 17, 2026 Filed Feb 19, 2026 21:34 UTC
Sheridan John FDirector · PRESIDENT & CEO
Exercise / conversionCommon Stock 5,983 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000014 · wk-form4_1771536871.xml · nonDerivative · entry 3

Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 127,091

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 17, 2026 Filed Feb 19, 2026 21:34 UTC
Sheridan John FDirector · PRESIDENT & CEO
Tax withholdingCommon Stock 1,963 $18.95 $37,198.85
Disclosure

SEC source: 0001438133-26-000014 · wk-form4_1771536871.xml · nonDerivative · entry 2

Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 121,108

F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Read SEC document
February 17, 2026 Filed Feb 19, 2026 21:34 UTC
Sheridan John FDirector · PRESIDENT & CEO
Exercise / conversionCommon Stock 5,471 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000014 · wk-form4_1771536871.xml · nonDerivative · entry 1

Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 123,071

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 17, 2026 Filed Feb 19, 2026 21:33 UTC
Hansen Shannon MarieEVP & Chief Legal Officer
Exercise / conversionRestricted Stock Unit · Derivative 1,097 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000012 · wk-form4_1771536816.xml · derivative · entry 10

Hansen Shannon Marie · CIK 0001908267 · EVP & Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,484

Underlying: Common Stock · 1,097 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F9 · security: Awarded on May 23, 2024 pursuant to the 2023 Plan.

F7 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.

F10 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

F10 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

Read SEC document
February 17, 2026 Filed Feb 19, 2026 21:33 UTC
Hansen Shannon MarieEVP & Chief Legal Officer
Exercise / conversionRestricted Stock Unit · Derivative 1,437 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000012 · wk-form4_1771536816.xml · derivative · entry 9

Hansen Shannon Marie · CIK 0001908267 · EVP & Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,437

Underlying: Common Stock · 1,437 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · security: Awarded on May 25, 2023 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan (the 2023 Plan).

F7 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.

F8 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

F8 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

Read SEC document
February 17, 2026 Filed Feb 19, 2026 21:33 UTC
Hansen Shannon MarieEVP & Chief Legal Officer
Exercise / conversionRestricted Stock Unit · Derivative 531 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000012 · wk-form4_1771536816.xml · derivative · entry 8

Hansen Shannon Marie · CIK 0001908267 · EVP & Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 531 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: Awarded on February 15, 2022 pursuant to the Tandem Diabetes Care Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the 2013 Plan).

F4 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan.

F5 · derivative.exercise_date: RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on 2/15/2023, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter.

F5 · derivative.expiration_date: RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on 2/15/2023, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter.

Read SEC document
February 17, 2026 Filed Feb 19, 2026 21:33 UTC
Hansen Shannon MarieEVP & Chief Legal Officer
Tax withholdingCommon Stock 452 $18.95 $8,565.40
Disclosure

SEC source: 0001438133-26-000012 · wk-form4_1771536816.xml · nonDerivative · entry 6

Hansen Shannon Marie · CIK 0001908267 · EVP & Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,276

F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Read SEC document
February 17, 2026 Filed Feb 19, 2026 21:33 UTC
Hansen Shannon MarieEVP & Chief Legal Officer
Exercise / conversionCommon Stock 1,097 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000012 · wk-form4_1771536816.xml · nonDerivative · entry 5

Hansen Shannon Marie · CIK 0001908267 · EVP & Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,728

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 17, 2026 Filed Feb 19, 2026 21:33 UTC
Hansen Shannon MarieEVP & Chief Legal Officer
Tax withholdingCommon Stock 592 $18.95 $11,218.40
Disclosure

SEC source: 0001438133-26-000012 · wk-form4_1771536816.xml · nonDerivative · entry 4

Hansen Shannon Marie · CIK 0001908267 · EVP & Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,631

F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Read SEC document
February 17, 2026 Filed Feb 19, 2026 21:33 UTC
Hansen Shannon MarieEVP & Chief Legal Officer
Exercise / conversionCommon Stock 1,437 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000012 · wk-form4_1771536816.xml · nonDerivative · entry 3

Hansen Shannon Marie · CIK 0001908267 · EVP & Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,223

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 17, 2026 Filed Feb 19, 2026 21:33 UTC
Hansen Shannon MarieEVP & Chief Legal Officer
Tax withholdingCommon Stock 219 $18.95 $4,150.05
Disclosure

SEC source: 0001438133-26-000012 · wk-form4_1771536816.xml · nonDerivative · entry 2

Hansen Shannon Marie · CIK 0001908267 · EVP & Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,786

F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Read SEC document
February 17, 2026 Filed Feb 19, 2026 21:33 UTC
Hansen Shannon MarieEVP & Chief Legal Officer
Exercise / conversionCommon Stock 531 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000012 · wk-form4_1771536816.xml · nonDerivative · entry 1

Hansen Shannon Marie · CIK 0001908267 · EVP & Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,005

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 15, 2026 Filed Jan 20, 2026 21:09 UTC
Kyrillos Jean-ClaudeEVP & Chief Operating Officer
Exercise / conversionRestricted Stock Unit · Derivative 3,636 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000003 · wk-form4_1768943392.xml · derivative · entry 3

Kyrillos Jean-Claude · CIK 0001804186 · EVP & Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,817

Underlying: Common Stock · 3,636 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Awarded on July 15, 2024 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.

F4 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 7/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

F4 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 7/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

Read SEC document
January 15, 2026 Filed Jan 20, 2026 21:09 UTC
Kyrillos Jean-ClaudeEVP & Chief Operating Officer
Tax withholdingCommon Stock 2,118 $21.07 $44,626.26
Disclosure

SEC source: 0001438133-26-000003 · wk-form4_1768943392.xml · nonDerivative · entry 2

Kyrillos Jean-Claude · CIK 0001804186 · EVP & Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,062

F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Read SEC document
January 15, 2026 Filed Jan 20, 2026 21:09 UTC
Kyrillos Jean-ClaudeEVP & Chief Operating Officer
Exercise / conversionCommon Stock 3,636 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000003 · wk-form4_1768943392.xml · nonDerivative · entry 1

Kyrillos Jean-Claude · CIK 0001804186 · EVP & Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,180

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 15, 2025 Filed Dec 17, 2025 21:02 UTC
Novara Mark DavidEVP & CHIEF COMMERCIAL OFFICER
Exercise / conversionRestricted Stock Unit · Derivative 7,415 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000229 · wk-form4_1766005331.xml · derivative · entry 3

Novara Mark David · CIK 0002000342 · EVP & CHIEF COMMERCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,658

Underlying: Common Stock · 7,415 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Awarded on December 15, 2023 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.

F4 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 12/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

F4 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 12/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.